Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Franklyn Ophthalmic Instruments

This article was originally published in The Gray Sheet

Executive Summary

Going public via proposed offering of 1.25 mil. units at $4 each. The units consist of one share of common stock and one Class A common stock purchase warrant. Each warrant allows the holder to purchase one share of common stock at an exercise price of $5 for a period of five years from the date of the prospectus. The Securities and Exchange Commission filing also covers 200,000 shares of common stock offered by selling stockholders and bridge lender's warrants to purchase 625,000 units, from which the company will not receive proceeds. J. Gregory & Company is underwriting. The Hayward, California-based distributor of non-surgical examination instruments says net proceeds of approximately $4 mil. will go towards the payment of subordinated convertible debentures, redemption of "certain shares" of preferred stock issued by the company to bridge lenders, acquisition of inventory, advertising, promotion, and general working capital purposes.

You may also be interested in...



Biohaven’s Oral CGRP Inhibitor Nurtec ODT Approved In The US For Acute Migraine

The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.

Surging China Coronavirus Trials Prompt Tougher Criteria

A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules. 

Perrigo Reports Broad Growth, But Investors Sour On Turnaround's Price Tag

Its reported worldwide consumer Q4 net sales increased 12.7%, or 16.4% adjusted for currency exchange rates, product launches and other changes from the prior-year period, to $1.1bn. The s results, though, sent share price plummeting $8.64, more than 14%, to $51.82.
UsernamePublicRestriction

Register

MT000501

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel